IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension

IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension

Abstract AV‐101 (imatinib) powder for inhalation, an investigational dry powder inhaled formulation of imatinib designed to target the underlying pathobiology of pulmonary arterial hypertension, was generally well tolerated in healthy adults in a phase 1 single and multiple ascending dose study. Inh...

Full description

Bibliographic Details
Main Authors: Hunter Gillies, Murali M. Chakinala, Benjamin T. Dake, Jeremy P. Feldman, Marius M. Hoeper, Marc Humbert, Zhi‐Cheng Jing, Jonathan Langley, Vallerie V. McLaughlin, Ralph W. Niven, Stephan Rosenkranz, Xiaosha Zhang, Nicholas S. Hill
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Pulmonary Circulation
Subjects:
dry powder inhaler
effectiveness
study design
tolerability
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/pul2.12352

Internet

https://doi.org/10.1002/pul2.12352

Similar Items